Ono earmarks $940m to gain rare blood cancer therapy from Ionis

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia vera (PV).

Mar 13, 2025 - 06:00
Ono earmarks $940m to gain rare blood cancer therapy from Ionis
Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia vera (PV).

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow